1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. Washington >
  6. Alloy Therapeutics Acquires Spannerwerks

M&A Deal Summary

Alloy Therapeutics Acquires Spannerwerks

On October 23, 2025, Alloy Therapeutics acquired life science company Spannerwerks

Acquisition Highlights
  • This is Alloy Therapeutics’ 2nd transaction in the Life Science sector.
  • This is Alloy Therapeutics’ 1st transaction in the United States.
  • This is Alloy Therapeutics’ 1st transaction in Washington.

M&A Deal Summary
Date 2025-10-23
Target Spannerwerks
Sector Life Science
Buyer(s) Alloy Therapeutics
Deal Type Add-on Acquisition

Target

Spannerwerks

Seattle, Washington, United States
Spannerwerks provides product development consulting that enables drug companies to execute throughout the drug development process. The company supports clients with hands-on support in situations when experience, expertise, and execution matter, such as filing an IND, starting up a clinical study, or preparing for commercialization. It partners with in-house teams, filling in resource gaps, integrating workstreams, and driving projects forward. Spannerwerks is based in Seattle, Washington.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Alloy Therapeutics

Lexington, Massachusetts, United States
Category Company
Sector Life Science
DESCRIPTION

Alloy Therapeutics is a biotechnology ecosystem company empowering the global scientific community to make better medicines together. Through a community of partners, Alloy democratizes access to tools, technologies, services, and company creation capabilities that are foundational for discovering and developing therapeutic biologics. Alloy Therapeutics is based in Lexington, Massachusetts.

DEAL STATS #
Overall 2 of 2
Sector: Life Science M&A 2 of 2
Type: Add-on Acquisition M&A Deals 2 of 2
State: Washington M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2025 M&A 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-12-09 deepCDR Biologics

Basel-Town, Switzerland

deepCDR Biologics is a developer of deep learning technology for antibody discovery and optimization. deepCDR Biologics was founded in 2019 and is based in Basel-Town, Switzerland.

Buy -
Mergr

Solution for

Product

Company

Legal